David Allen

Prof. David Allen

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2021 in Indoor Air
Verified
Journal Article
Open access
PDF file
AAAlicia XY Ang
Alicia XY Ang
ILIrvan Luhung
Irvan Luhung
BABintou A. Ahidjo
Bintou A. Ahidjo
DDDaniela I. Drautz‐Moses
Daniela I. Drautz‐Moses
PTPaul A. Tambyah
Paul A. Tambyah
SSStephan C. Schuster
Stephan C. Schuster
Reliable methods to detect the presence of SARS-CoV-2 at venues where people gather are essential for epidemiological surveillance to guide public policy. Communal screening of air in a highly crowded space has the potential to provide early warning on the presence and potential transmission of SARS-CoV-2 as suggested by studies early in the epidemic. As hospitals and public facilities apply varying degrees of restrictions and regulations, it is important to provide multiple methodological options to enable environmental SARS-CoV-2 surveillance under different conditions. This study assessed the feasibility of using high-flowrate air samplers combined with RNA extraction kit designed for environmental sample to perform airborne SARS-CoV-2 surveillance in hospital setting, tested by RT-qPCR. The success rate of the air samples in detecting SARS-CoV-2 was then compared with surface swab samples collected in the same proximity. Additionally, positive RT-qPCR samples underwent viral culture to assess the viability of the sampled SARS-CoV-2. The study was performed in inpatient ward environments of a quaternary care university teaching hospital in Singapore housing active COVID-19 patients within the period of February to May 2020. Two types of wards were tested, naturally ventilated open-cohort ward and mechanically ventilated isolation ward. Distances between the site of air sampling and the patient cluster in the investigated wards were also recorded. No successful detection of airborne SARS-CoV-2 was recorded when 50 L/min air samplers were used. Upon increasing the sampling flowrate to 150 L/min, our results showed a high success rate in detecting the presence of SARS-CoV-2 from the air samples (72%) compared to the surface swab samples (9.6%). The positive detection rate of the air samples along with the corresponding viral load could be associated with the distance between sampling site and patient. The furthest distance from patient with PCR-positive air samples was 5.5 m. The airborne SARS-CoV-2 detection was comparable between the two types of wards with 60%–87.5% success rate. High prevalence of the virus was found in toilet areas, both on surfaces and in air. Finally, no successful culture attempt was recorded from the environmental air or surface samples.

30 June 2022 in npj Digital Medicine
Verified
Journal Article
Open access
PDF file
ABAgata Blasiak
Agata Blasiak
ATAnh T. L. Truong
Anh T. L. Truong
ARAlexandria Remus
Alexandria Remus
LHLissa Hooi
Lissa Hooi
SSShirley Gek Kheng Seah
Shirley Gek Kheng Seah
DHDean Ho
Dean Ho
IDentif.AI-x, a clinically actionable artificial intelligence platform, was used to rapidly pinpoint and prioritize optimal combination therapies against COVID-19 by pairing a prospective, experimental validation of multi-drug efficacy on a SARS-CoV-2 live virus and Vero E6 assay with a quadratic optimization workflow. A starting pool of 12 candidate drugs developed in collaboration with a community of infectious disease clinicians was first narrowed down to a six-drug pool and then interrogated in 50 combination regimens at three dosing levels per drug, representing 729 possible combinations. IDentif.AI-x revealed EIDD-1931 to be a strong candidate upon which multiple drug combinations can be derived, and pinpointed a number of clinically actionable drug interactions, which were further reconfirmed in SARS-CoV-2 variants B.1.351 (Beta) and B.1.617.2 (Delta). IDentif.AI-x prioritized promising drug combinations for clinical translation and can be immediately adjusted and re-executed with a new pool of promising therapies in an actionable path towards rapidly optimizing combination therapy following pandemic emergence.

17 August 2022 in ACS Nano
Verified
Journal Article
Closed access
ABAgata Blasiak
Agata Blasiak
ATAnh T. L. Truong
Anh T. L. Truong
PWPeter Wang
Peter Wang
LHLissa Hooi
Lissa Hooi
DCDe Hoe Chye
De Hoe Chye
DHDean Ho
Dean Ho

25 February 2025 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
MKMatthew Chung Yi Koh
Matthew Chung Yi Koh
JNJinghao Nicholas Ngiam
Jinghao Nicholas Ngiam
KCKa Lip Chew
Ka Lip Chew
NSNares Smitasin
Nares Smitasin
LLLionel Hon-Wai Lum
Lionel Hon-Wai Lum
DADavid Allen
David Allen
Bloodstream infections with the non-fermenting Gram-negative organisms Stenotrophomonas maltophilia, Elizabethkingia spp. or Chryseobacterium spp. are observed in nosocomial settings. Comparative description of their clinical presentation, microbiological characteristics, treatment options and outcomes remain to be investigated. We performed a retrospective single-centre analysis of bloodstream infections with the abovementioned three organisms from 1 Jan 2012 to 30 Jun 2024. A total of 349 distinct encounters (from 322 unique patients) were identified with bacteraemia. Stenotrophomonas maltophilia was the commonest (197/349, 56.4%), followed by Elizabethkingia spp. (127/349, 36.4%) and Chryseobacterium spp. (25/349, 7.2%). Prior carbapenem exposure was observed in 59.9% of cases. The majority were related to central lines (58.2%). Most cases were nosocomial in onset (82.5%), and a third were from the intensive care unit (32.1%). A significant proportion of our Stenotrophomonas maltophilia (32.8%) and Chryseobacterium spp. (22.7%) isolates were resistant to levofloxacin, while a majority of the organisms retained susceptibility to trimethoprim-sulfamethoxazole (TMP-SMX) and minocycline. Dual antibiotics were used in a minority of encounters (23/349, 6.6%). Mortality was high across infections with the three organisms, but highest amongst those with Stenotrophomonas maltophilia bacteraemia (41.6%), followed by Elizabethkingia spp. (29.9%) and Chryseobacterium spp. (20.0%). Stenotrophomonas, Elizabethkingia or Chryseobacterium spp bacteraemia was associated with significant mortality. Most cases were nosocomial in acquisition, with prior carbapenem exposure or indwelling central catheters. Fluoroquinolone resistance was common for Stenotrophomonas maltophilia and Chryseobacterium spp., but less prevalent in Elizabethkingia spp., while TMP-SMX and minocycline retained susceptibility. Monitoring these trends would be critical in guiding empiric therapy for these organisms.

1 May 2021 in JAMA Otolaryngology–Head & Neck Surgery
Verified
Journal Article
Open access
PDF file
JTJoshua K. Tay
Joshua K. Tay
GCGail B. Cross
Gail B. Cross
STSong Tar Toh
Song Tar Toh
CLChun Kiat Lee
Chun Kiat Lee
JLJerold Loh
Jerold Loh
DADavid Allen
David Allen
Since December 2019, the coronavirus disease 2019 (COVID-19) pandemic has spread to 191 countries, with 76 million cases worldwide and more than 1.6 million fatalities.1 One of the World Health Organization’s strategic objectives is to control clusters and prevent community transmission by rapidly identifying all cases.2 The identification of cases is typically performed using material collected from a nasopharyngeal swab, which is tested for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using reverse-transcriptase polymerase chain reaction (RT-PCR). Even as the pandemic continues to escalate, many countries that initially achieved good control of the pandemic have experienced resurgences and will continue to have high testing requirements to reestablish control.3-5 The gradual opening of borders between countries and the testing of travelers will also continue to place pressure on testing capacities.

10 January 2023 in Frontiers in Public Health
Verified
Journal Article
Open access
KTKai Sen Tan
Kai Sen Tan
AAAlicia Xin Yu Ang
Alicia Xin Yu Ang
DTDouglas Jie Wen Tay
Douglas Jie Wen Tay
JSJyoti Somani
Jyoti Somani
ANAlexander Jet Yue Ng
Alexander Jet Yue Ng
DADavid Allen
David Allen
Background and objectives: The high transmissibility of SARS-CoV-2 has exposed weaknesses in our infection control and detection measures, particularly in healthcare settings. Aerial sampling has evolved from passive impact filters to active sampling using negative pressure to expose culture substrate for virus detection. We evaluated the effectiveness of an active air sampling device as a potential surveillance system in detecting hospital pathogens, for augmenting containment measures to prevent nosocomial transmission, using SARS-CoV-2 as a surrogate.Methods: We conducted air sampling in a hospital environment using the AerosolSenseTM air sampling device and compared it with surface swabs for their capacity to detect SARS-CoV-2.Results: When combined with RT-qPCR detection, we found the device provided consistent SARS-CoV-2 detection, compared to surface sampling, in as little as 2 h of sampling time. The device also showed that it can identify minute quantities of SARS-CoV-2 in designated “clean areas” and through a N95 mask, indicating good surveillance capacity and sensitivity of the device in hospital settings.Conclusion: Active air sampling was shown to be a sensitive surveillance system in healthcare settings. Findings from this study can also be applied in an organism agnostic manner for surveillance in the hospital, improving our ability to contain and prevent nosocomial outbreaks.